Difference between revisions of "Penpulimab (Anniko)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
| − | |||
==Mechanism of action== | ==Mechanism of action== | ||
PD-1 inhibitor | PD-1 inhibitor | ||
| Line 12: | Line 11: | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' AK105 | *'''Code name:''' AK105 | ||
| + | *'''Brand name:''' Anniko | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 12:40, 26 June 2023
Mechanism of action
PD-1 inhibitor
Diseases for which it is used
History of changes in NMPA indication
- 2021-08-05: Initial approval for treatment of patients with relapsed or refractory ("r/r") classic Hodgkin’s lymphoma ("cHL") after at least second-line systemic chemotherapy treatment.
- 2023-01-15: Approved in combination with chemotherapy as the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). (Based on AK105-302)
Also known as
- Code name: AK105
- Brand name: Anniko